Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
30 mars 2023 16h30 HE
|
Structure Therapeutics Inc.
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public...
Offshore Wind Industry Power Players Headline 2023 IPF
29 mars 2023 19h26 HE
|
Business Network for Offshore Wind
Baltimore, March 29, 2023 (GLOBE NEWSWIRE) -- Exactly two years after President Biden announced a national target to deploy 30 GW of offshore wind energy capacity by 2030, key government and...
Media Advisory: Interior Secretary Haaland, White House Climate Advisor Zaidi, Maryland Governor Moore to headline major offshore wind conference
27 mars 2023 10h03 HE
|
Business Network for Offshore Wind
Baltimore, March 27, 2023 (GLOBE NEWSWIRE) -- The tenth annual International Offshore Wind Partnering Forum (IPF), hosted by the Business Network for Offshore Wind, will kick off this Tuesday, March...
Interior Secretary Haaland, White House Climate Advisor Zaidi, Maryland Governor Moore to Headline 2023 International Offshore Wind Partnering Forum
14 mars 2023 08h30 HE
|
Business Network for Offshore Wind
Baltimore, March 14, 2023 (GLOBE NEWSWIRE) -- The Business Network for Offshore Wind today announced U.S. Secretary of the Interior Deb Haaland, White House National Climate Advisor Ali Zaidi, and...
Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results
24 févr. 2023 07h30 HE
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its financial results for the fiscal year ended December...
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
17 févr. 2023 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close....
Insilico Medicine Receives FDA Orphan Drug Designation for Generative AI Discovered and Designed Drug for Idiopathic Pulmonary Fibrosis
08 févr. 2023 09h00 HE
|
InSilico Medicine
New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, today announced that...
硕迪生物宣布完成经增发的首次公开募股包括承销商全面行使购买额外美国存托股票的选择权
07 févr. 2023 16h00 HE
|
Structure Therapeutics Inc.
旧金山和上海, Feb. 08, 2023 (GLOBE NEWSWIRE) --...
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
07 févr. 2023 16h00 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
硕迪生物宣布经增发的首次公开募股的定价
02 févr. 2023 20h59 HE
|
Structure Therapeutics Inc.
加利福尼亚州旧金山和中国上海, Feb. 03, 2023 (GLOBE NEWSWIRE) -- 硕迪生物技术有限公司(纳斯达克股票代码:GPCR)是一家临床阶段的全球化生物制药公司,致力于口服小分子药物的创新研发以治疗代谢性和肺部疾病。今日,公司宣布其经增发的首次公开募股的定价。公司拟发行10,740,000股美国存托股票(ADS),每股ADS代表三股普通股,公开发行价格为每股ADS...